563 The Effect of Once-Weekly Semaglutide on MACE and Blood Pressure by Race and Ethnicity: SUSTAIN 6 Post Hoc Analysis

In SUSTAIN 6, once-weekly semaglutide added to standard of care significantly reduced major adverse cardiovascular (CV) events (MACE: nonfatal myocardial infarction [MI], nonfatal stroke, CV death) vs placebo over a median 2 years in subjects with type 2 diabetes at high CV risk. This post hoc analysis assessed the effect of semaglutide vs placebo on MACE and blood pressure (BP) by race/ethnicity.

Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: T. Davis, C. Desouza, S. Bain, T. Gondolf, T. Hansen, I. Holst, R. Rea, J. Seufert Source Type: research